Around 10% of receptor tyrosine kinases lack catalytic activity and are termed pseudokinases. Some of these molecules are involved in cancer development and resistance to treatment. Currently, several clinical trials study how targeting their expression stops cancer growth. In this project, we investigate how two of these receptors, ROR1 and ROR2, initiate signaling in cells. We will also investigate how ROR1 expression promotes drug resistance in ovarian cancer. The results of this project are expected to be useful in designing new treatment options for cancers that express ROR1.

2024

2028